Paratek $PRTK did not soar as much as we hoped after its positive p3 for ABSSSI for omadacycline. It just went up about 20% and came down again because the company took the opportunity to sell some more shares. It didn’t get anywhere near where it was last year - $30. So, when its next p3 trial results for omadacycline for CABP are declared next year, or when there’s commercialization of omadacycline in ABSSSI, I expect a lot more upside. Therefore, PRTK is a definite consideration for buying right now.

*** L3 or above subscription required to read the rest of the article ... Login or Subscribe/Upgrade here